Skip to content

Welcome to Discover Pharma! Today is : October 20, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Phase 3

  • Biotech & Pharma Business,Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    BridgeBio gets FDA Priority Review for oral infigratinib in achondroplasia

    BridgeBio has secured FDA Priority Review for its oral infigratinib [...]

    October 7, 2026
  • Advanced Therapies,Clinical & Regulatory,Drug Delivery & Formulation,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    Trixeo approved in EU for asthma

    AstraZeneca’s Trixeo has been approved in the EU as a [...]

    September 30, 2026
  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Research & Development,Therapeutic Areas

    Novadip secures €10.4M to advance pivotal Phase 3 trial

    Novadip Biosciences has secured €10.4 million in convertible financing to [...]

    September 21, 2026
  • Biotech & Pharma Business,Manufacturing & Supply Chain,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    Telix to acquire ITM in $1.65BN radiopharmaceutical deal

    Telix has agreed to acquire ITM Isotope Technologies Munich in [...]

    September 21, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Karyopharm seeks FDA accelerated approval for selinexor in myelofibrosis

    Karyopharm Therapeutics has submitted an application to the FDA seeking [...]

    September 14, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Tezspire meets Phase 3 endpoints in eosinophilic esophagitis

    AstraZeneca and Amgen’s Tezspire has met both co-primary and key [...]

    August 28, 2026
  • Advanced Therapies,Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development

    Agenus reports deep responses with immunotherapy in Phase 2 colon cancer study

    Agenus has reported deep tumour responses and no observed colorectal [...]

    August 27, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    NICE recommends glycopyrronium cream for severe underarm sweating

    NICE has recommended glycopyrronium bromide cream as an option for [...]

    August 17, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Digital & Data,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development

    Remepy raises $36M to advance Parkinson’s drug into Phase 3

    Remepy has raised $36M in a Series A financing round [...]

    August 14, 2026
  • Central Nervous System,Clinical & Regulatory,Research & Development,Therapeutic Areas

    Zilucoplan accepted for eligible myasthenia gravis patients in NHS Scotland

    Zilucoplan has been accepted for restricted use in NHS Scotland [...]

    August 11, 2026
12Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Olink assay correlates with ELISA for measuring endothelin-1
    Categories: Clinical & Regulatory, Research & Development
  • BridgeBio gets FDA Priority Review for oral infigratinib in achondroplasia
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • ViiV’s Cabenuva achieves superior viral suppression in CROWN Phase 3b study
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top